Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Turning point therapeutics, inc. save search
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
Published: 2022-04-12 (Crawled : 21:00) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 6.13%
H: 26.26%
C: 17.9%
topline therapeutics review positive phase 1
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
Published: 2022-03-21 (Crawled : 13:30) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -2.48%
H: 1.22%
C: -5.25%
pos enroll therapeutics positive
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted grant designation
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | $14.2 -0.77% -0.88% 640K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer
Published: 2021-01-29 (Crawled : 14:00) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 3.99%
H: 3.22%
C: -0.01%
positive cancer phase 2 lung cancer
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer
Published: 2020-12-08 (Crawled : 22:00) - biospace.com/
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy treatment designation
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Published: 2020-12-08 (Crawled : 14:02) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: 4.68%
H: 4.34%
C: 3.86%
cancer therapy positive fda lung cancer breakthrough therapy tyrosine kinase inhibitor designation
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.